相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Altered Activation of Endothelial Anti- and Proapoptotic Pathways by High-Density Lipoprotein from Patients with Coronary Artery Disease Role of High-Density Lipoprotein-Proteome Remodeling
Meliana Riwanto et al.
CIRCULATION (2013)
The difficult search for a 'partner' of statins in lipid-targeted prevention of vascular events: the re-emergence and fall of niacin
Ulf Landmesser
EUROPEAN HEART JOURNAL (2013)
HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment
Richard Haynes et al.
EUROPEAN HEART JOURNAL (2013)
Abnormal High-Density Lipoprotein Induces Endothelial Dysfunction via Activation of Toll-like Receptor-2
Thimoteus Speer et al.
IMMUNITY (2013)
Executive Summary: Heart Disease and Stroke Statistics-2012 Update A Report From the American Heart Association
Veronique L. Roger et al.
CIRCULATION (2012)
Cholesterol Efflux Potential and Antiinflammatory Properties of High-Density Lipoprotein After Treatment With Niacin or Anacetrapib
Laurent Yvan-Charvet et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2010)
Evidence That Niacin Inhibits Acute Vascular Inflammation and Improves Endothelial Dysfunction Independent of Changes in Plasma Lipids
Ben J. Wu et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2010)
Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis
Eric Bruckert et al.
ATHEROSCLEROSIS (2010)
Regulation of Hepatic ApoC3 Expression by PGC-1β Mediates Hypolipidemic Effect of Nicotinic Acid
Carlos Hemandez et al.
CELL METABOLISM (2010)
High-Density Lipoprotein Suppresses the Type I Interferon Response, a Family of Potent Antiviral Immunoregulators, in Macrophages Challenged With Lipopolysaccharide
Masashi Suzuki et al.
CIRCULATION (2010)
Endothelial-Vasoprotective Effects of High-Density Lipoprotein Are Impaired in Patients With Type 2 Diabetes Mellitus but Are Improved After Extended-Release Niacin Therapy
Sajoscha A. Sorrentino et al.
CIRCULATION (2010)
Lipoprotein(a) as a cardiovascular risk factor: current status
Borge G. Nordestgaard et al.
EUROPEAN HEART JOURNAL (2010)
Effect of Fenofibrate and Niacin on Intrahepatic Triglyceride Content, Very Low-Density Lipoprotein Kinetics, and Insulin Action in Obese Subjects with Nonalcoholic Fatty Liver Disease
Elisa Fabbrini et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis) Final Results and the Impact of Medication Adherence, Dose, and Treatment Duration
Todd C. Villines et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
A First-in-Man, Randomized, Placebo-Controlled Study to Evaluate the Safety and Feasibility of Autologous Delipidated High-Density Lipoprotein Plasma Infusions in Patients With Acute Coronary Syndrome
Ron Waksman et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
C. Baigent et al.
LANCET (2010)
Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trial
Jane Armitage et al.
LANCET (2010)
Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease.
Christopher P. Cannon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Population Trends in the Incidence and Outcomes of Acute Myocardial Infarction.
Robert W. Yeh et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
ATP-Binding Cassette Transporters and HDL Suppress Hematopoietic Stem Cell Proliferation
Laurent Yvan-Charvet et al.
SCIENCE (2010)
Niacin stimulates adiponectin secretion through the GPR109A receptor
Eric P. Plaisance et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2009)
The HDL proteome: a marker-and perhaps mediator-of coronary artery disease
Jay W. Heinecke
JOURNAL OF LIPID RESEARCH (2009)
Effects of High-Dose Modified-Release Nicotinic Acid on Atherosclerosis and Vascular Function A Randomized, Placebo-Controlled, Magnetic Resonance Imaging Study
Justin M. S. Lee et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
Update on strategies to increase HDL quantity and function
Danielle Duffy et al.
NATURE REVIEWS CARDIOLOGY (2009)
Extended-Release Niacin or Ezetimibe and Carotid Intima-Media Thickness
Allen J. Taylor et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Mechanism of action of niacin
Vaijinath S. Kamanna et al.
AMERICAN JOURNAL OF CARDIOLOGY (2008)
Nicotinic acid: Pharmacological effects and mechanisms of action
Andreas Gille et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY (2008)
Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and apoB-containing lipoproteins
Stefania Lamon-Fava et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2008)
Niacin Increases HDL by Reducing Hepatic Expression and Plasma Levels of Cholesteryl Ester Transfer Protein in APOE*3Leiden.CETP Mice
Jose W. A. van der Hoorn et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2008)
Combined statin and niacin therapy remodels the high-density lipoprotein proteome
Pattie S. Green et al.
CIRCULATION (2008)
Effects of a niacin receptor partial agonist, MK-0354, on plasma free fatty acids, lipids, and cutaneous flushing in humans
Eseng Lai et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2008)
Cholesterol efflux pathways and other potential mechanisms involved in the athero-protective effect of high density lipoproteins
A. R. Tall
JOURNAL OF INTERNAL MEDICINE (2008)
Niacin inhibits surface expression of ATP synthase beta chain in HepG2 cells: implications for raising HDL
Lin-Hua Zhang et al.
JOURNAL OF LIPID RESEARCH (2008)
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Paul M. Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Effects of torcetrapib in patients at high risk for coronary events
Philip J. Barter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
The effects of extended-release niacin on carotid intimal media thickness, endothelial function and inflammatory markers in patients with the metabolic syndrome
M. Thoenes et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2007)
HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events
Philip Barter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis
Stephen J. Nicholls et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL
Tomas Vaisar et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Should both HDL-C and LDL-C be targets for lipid therapy? A review of current evidence
B. Greg Brown et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2007)
Torcetrapib and atherosclerosis: what happened and where do we go from here?
Peter P. Toth
FUTURE LIPIDOLOGY (2007)
The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3
Allen J. Taylor et al.
CURRENT MEDICAL RESEARCH AND OPINION (2006)
Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease
Jeffrey T. Kuvin et al.
AMERICAN JOURNAL OF CARDIOLOGY (2006)
Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy
Christopher P. Cannon et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2006)
LXR-induced redistribution of ABCG1 to plasma membrane in macrophages enhances cholesterol mass efflux to HDL
Nan Wang et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2006)
Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials
Joao Costa et al.
BMJ-BRITISH MEDICAL JOURNAL (2006)
ABCA1 and ABCG1 synergize to mediate cholesterol export to apoA-I
IC Gelissen et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2006)
Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age
DM Lloyd-Jones et al.
CIRCULATION (2006)
Dyslipidemia prevalence, treatment, and control in the Multi-Ethnic Study of Atherosclerosis (MESA) - Gender, ethnicity, and coronary artery calcium
DC Goff et al.
CIRCULATION (2006)
Standards of medical care in diabetes
D Power
DIABETES CARE (2006)
Statins: Beneficial or adverse for glucose metabolism
Jun Sasaki et al.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2006)
Mechanisms of disease: proatherogenic HDL - an evolving field
Mohamad Navab et al.
NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM (2006)
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins
C Baigent et al.
LANCET (2005)
Relation of characteristics of metabolic syndrome to short-term prognosis and effects of intensive statin therapy after acute coronary syndrome: An analysis of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial
GG Schwartz et al.
DIABETES CARE (2005)
ABCG1 redistributes cell cholesterol to domains removable by high density lipoprotein but not by lipid-depleted apolipoproteins
AM Vaughan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Elevated high-density lipoprotein cholesterol levels are protective against plaque progression - A follow-up study of 1952 persons with carotid atherosclerosis - The Tromso study
SH Johnsen et al.
CIRCULATION (2005)
Niaspan®:: creating a new concept for raising HDL-cholesterol
M McGovern
EUROPEAN HEART JOURNAL SUPPLEMENTS (2005)
Intensive lipid lowering with atorvastatin in patients with stable coronary disease
JC LaRosa et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Opportunity for intervention to achieve American Heart Association guidelines for optimal lipid levels in high-risk women in a managed care setting
L Mosca et al.
CIRCULATION (2005)
ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation
MA Kennedy et al.
CELL METABOLISM (2005)
A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: Effects on progression of coronary heart disease and clinical events
EJ Whitney et al.
ANNALS OF INTERNAL MEDICINE (2005)
Effect of atorvastatin on high density lipoprotein cholesterol and its relationship with coronary events: a subgroup analysis of the GREek Atorvastatin and Coronary heart-disease Evaluation (GREACE) Study
VG Athyros et al.
CURRENT MEDICAL RESEARCH AND OPINION (2004)
Intensive versus moderate lipid lowering with statins after acute coronary syndromes
CP Cannon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Stimulation of CD36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin
T Rubic et al.
BIOCHEMICAL PHARMACOLOGY (2004)
Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells
SH Ganji et al.
JOURNAL OF LIPID RESEARCH (2004)
Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2 - A double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins
AJ Taylor et al.
CIRCULATION (2004)
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines
SM Grundy et al.
CIRCULATION (2004)
Relation between high-density lipoprotein cholesterol and peripheral vasomotor function
JT Kuvin et al.
AMERICAN JOURNAL OF CARDIOLOGY (2003)
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA):: a multicentre randomised controlled trial
PS Sever et al.
LANCET (2003)
Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care - The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT-LLT)
CD Furberg et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2002)
Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial
J Shepherd et al.
LANCET (2002)
Antioxidant vitamins and lipid therapy - End of a long romance?
BG Brown et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2002)
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial
R Collins et al.
LANCET (2002)
Niacin treatment of the atherogenic lipid profile and Lp(a) in diabetes
J Pan et al.
DIABETES OBESITY & METABOLISM (2002)
Comparison of extended-release niacin and atorvastatin monotherapies and combination treatment of the atherogenic lipid profile in diabetes mellitus
JT Van et al.
AMERICAN JOURNAL OF CARDIOLOGY (2002)
Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans - A randomized phase II dose-response study
GJ de Grooth et al.
CIRCULATION (2002)
Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia
ML Kashyap et al.
AMERICAN JOURNAL OF CARDIOLOGY (2002)
Oral administration of an apo A-I mimetic peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol
M Navab et al.
CIRCULATION (2002)
Prevalence of the metabolic syndrome among US adults - Findings from the Third National Health and Nutrition Examination Survey
ES Ford et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2002)
Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease
BG Brown et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Hypertriglyceridemic hyperapoB: The unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus
AD Sniderman et al.
ANNALS OF INTERNAL MEDICINE (2001)
Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia
JM McKenney et al.
AMERICAN JOURNAL OF CARDIOLOGY (2001)
Effects of endurance exercise training on plasma HDL cholesterol levels depend on levels of triglycerides -: Evidence from men of the health, risk factors, exercise training and genetics (HERITAGE) family study
C Couillard et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2001)
Response of blood lipids to exercise training alone or combined with dietary intervention
AS Leon et al.
MEDICINE AND SCIENCE IN SPORTS AND EXERCISE (2001)
Blood lipid and lipoprotein adaptations to exercise - A quantitative analysis
JL Durstine et al.
SPORTS MEDICINE (2001)
分享论文
